A randomized, double-blind, experimental study evaluating the efficiency and safety
for the VGuard device in the treatment of mild cognitive impairment (MCI).
for the VGuard device in the treatment of mild cognitive impairment (MCI).
Dear Sir or Madam
We would like to invite you to participate in the study named: A randomized, double-blind, experimental study evaluating the efficiency and safety for the VGuard device in the treatment of mild cognitive impairment (MCI).
The primary objective of the study is to determine the efficacy and safety for the new medical device. Results of this study will be used to provide evidence of efficacy and safety of Neuromedical's devices for treatment of patients with mild cognitive impairment.
The primary objective of the study is to determine the efficacy and safety for the new medical device. Results of this study will be used to provide evidence of efficacy and safety of Neuromedical's devices for treatment of patients with mild cognitive impairment.
Biostat is responsible for eCRF development and data management.
Bioscience is responsible for project management and monitoring.
